6.30
전일 마감가:
$7.12
열려 있는:
$6.35
하루 거래량:
4.21M
Relative Volume:
1.52
시가총액:
$496.37M
수익:
$214.30M
순이익/손실:
$162.50M
주가수익비율:
3.0685
EPS:
2.0531
순현금흐름:
$74.42M
1주 성능:
-14.29%
1개월 성능:
-14.29%
6개월 성능:
-49.19%
1년 성능:
-37.69%
CorMedix Inc Stock (CRMD) Company Profile
명칭
CorMedix Inc
전화
908-517-9500
주소
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Compare CRMD vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
CRMD
CorMedix Inc
|
6.30 | 560.98M | 214.30M | 162.50M | 74.42M | 2.0531 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-20 | 업그레이드 | D. Boral Capital | Hold → Buy |
| 2025-06-30 | 다운그레이드 | D. Boral Capital | Buy → Hold |
| 2025-06-30 | 개시 | H.C. Wainwright | Buy |
| 2025-03-07 | 개시 | Leerink Partners | Outperform |
| 2025-01-13 | 개시 | D. Boral Capital | Buy |
| 2024-08-26 | 개시 | Rodman & Renshaw | Buy |
| 2023-08-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-02-17 | 개시 | Needham | Buy |
| 2020-09-29 | 개시 | JMP Securities | Mkt Outperform |
| 2020-09-21 | 개시 | Truist | Buy |
| 2019-12-18 | 개시 | B. Riley FBR | Buy |
| 2019-03-26 | 재확인 | H.C. Wainwright | Buy |
| 2018-12-06 | 개시 | ROTH Capital | Buy |
| 2017-09-25 | 재확인 | H.C. Wainwright | Buy |
| 2017-08-10 | 재확인 | Rodman & Renshaw | Buy |
| 2017-05-05 | 재확인 | Rodman & Renshaw | Buy |
| 2016-11-11 | 재확인 | FBR & Co. | Outperform |
| 2016-03-17 | 재확인 | FBR Capital | Outperform |
| 2016-03-03 | 개시 | FBR Capital | Outperform |
| 2015-11-16 | 재확인 | ROTH Capital | Neutral |
| 2015-10-29 | 재확인 | ROTH Capital | Neutral |
| 2015-05-06 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2014-12-08 | 재확인 | ROTH Capital | Buy |
| 2011-10-03 | 다운그레이드 | Maxim Group | Buy → Hold |
모두보기
CorMedix Inc 주식(CRMD)의 최신 뉴스
Truist reiterates CorMedix stock rating on steady guidance - Investing.com
CorMedix Shares Fall After Q4 Profit Miss - marketscreener.com
CorMedix: Fourth Quarter Financial Results Overview - Bitget
CorMedix (CRMD) Q4 2025 Earnings Call Transcript - AOL.com
CorMedix stock falls after earnings miss (CRMD:NASDAQ) - Seeking Alpha
Why Did CRMD Stock Tumble Over 11% Today? - Asianet Newsable
Earnings call transcript: CorMedix Q4 2025 results miss EPS, stock dips - Investing.com Nigeria
CorMedix (CRMD) Lags Q4 Earnings Estimates - Yahoo Finance
CorMedix Q4 2025 Earnings Call Transcript - MarketBeat
Cormedix Earnings Review: Q4 Summary - Benzinga
CorMedix earnings missed by $0.69, revenue topped estimates - Investing.com
CorMedix: Q4 Earnings Snapshot - KVUE
CorMedix reports Q4 revenue of $128.6M, reaffirms 2026 guidance - Investing.com
CORMEDIX ($CRMD) Releases Q4 2025 Earnings - Quiver Quantitative
CorMedix stock falls 5% on fourth quarter earnings miss - Investing.com India
CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
CorMedix reports Q4 revenue of $128.6M, reaffirms 2026 guidance By Investing.com - Investing.com UK
CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - The Manila Times
Cormedix Stock Pre-Market (+6.2%) : Technical Move Ahead of Key Q2 Catalyst - Trefis
Cormedix Earnings Preview - Benzinga
CRMD Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Earnings Preview: CorMedix to Report Financial Results Pre-market on March 05 - 富途牛牛
CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026 - marketscreener.com
CorMedix Inc. to Report Fourth Quarter and Full Year 2025 - GlobeNewswire
Responsive Playbooks and the CRMD Inflection - Stock Traders Daily
CRMD Earnings History & Surprises | EPS & Revenue Results | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
Is It Time To Revisit CorMedix (CRMD) After Its Sharp Year To Date Decline? - Yahoo Finance
CRMD SEC FilingsCormedix 10-K, 10-Q, 8-K Forms - Stock Titan
CorMedix Expands With Melinta Buy As Valuation Gap Draws Attention - Sahm
CorMedix Inc. (CRMD): Investor Outlook With A Promising 102% Upside Potential - DirectorsTalk Interviews
Evaluating CorMedix (CRMD) Valuation As Melinta Acquisition And DefenCath Outlook Refocus Investor Attention - simplywall.st
CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Bet? - TradingView
Should Investors Buy, Sell or Hold CRMD Stock Ahead of Q4 Earnings? - Finviz
A Pivotal Spring Agenda for CorMedix Investors - AD HOC NEWS
CorMedix Inc. (CRMD) board approves multi-year $75M stock buyback - MSN
Understanding the Setup: (CRMD) and Scalable Risk - Stock Traders Daily
Buyback Watch: Why is CorMedix Inc stock going downMarket Growth Review & Daily Volume Surge Trade Alerts - baoquankhu1.vn
CorMedix Down 27% in 3 Months: Is It Time to Sell the Stock? - Bitget
Why CorMedix Inc. stock attracts high net worth investorsRate Cut & Free High Return Stock Watch Alerts - mfd.ru
What is CorMedix Inc.’s book value per shareJuly 2025 Highlights & Reliable Breakout Stock Forecasts - mfd.ru
CorMedix Inc. (CRMD) Investor Outlook: 101.86% Potential Upside Sparks Interest - DirectorsTalk Interviews
Can CorMedix's Melinta acquisition aid growth beyond DefenCath? - MSN
CorMedix Buyback And Melinta Integration Reframe Anti Infectives Growth Story - Yahoo Finance
Aug Wrap: What makes CorMedix Inc stock attractive todayMarket Sentiment Summary & Capital Protection Trade Alerts - baoquankhu1.vn
CorMedix to Participate in Upcoming Investor Conferences - GlobeNewswire
CorMedix Inc (CRMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):